NJ State Employees Deferred Compensation Plan’s Protalix BioTherapeutics PLX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,000	Closed	-$78K	–	385
2015 Q2	$78K	Hold	4,000	–	–	0.02%	368
2015 Q1	$71K	Hold	4,000	–	–	0.01%	377
2014 Q4	$74K	Hold	4,000	–	–	0.01%	379
2014 Q3	$97K	Hold	4,000	–	–	0.02%	376
2014 Q2	$146K	Hold	4,000	–	–	0.03%	377
2014 Q1	$183K	Hold	4,000	–	–	0.04%	378
2013 Q4	$156K	Hold	4,000	–	–	0.03%	387
2013 Q3	$181K	Hold	4,000	–	–	0.04%	376
2013 Q2	$196K	Buy	+4,000	New	+$212K	0.04%	367

Other funds holding PLX

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $659M AUM 50.04% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's PLX Position: Q3 2015 in Review

NJ State Employees Deferred Compensation Plan sold out of Protalix BioTherapeutics (PLX) in Q3 2015, closing a stake of 4,000 shares — an estimated $78K sold.

NJ State Employees Deferred Compensation Plan first reported a position in PLX in Q2 2013 and held it in 9 quarters. The position peaked at $196K in Q2 2013. 34 funds tracked by Wall St. Rank hold PLX as of Q3 2015.

NJ State Employees Deferred Compensation Plan reported no remaining Protalix BioTherapeutics position as of Q3 2015 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 4,000 Protalix BioTherapeutics shares in Q3 2015, an estimated $78K.
NJ State Employees Deferred Compensation Plan first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 9 quarters.
NJ State Employees Deferred Compensation Plan's Protalix BioTherapeutics position peaked at $196K in Q2 2013.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2015.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2015, filed 2 Nov 2015.